Onco-Innovations Advances Novel Cancer Therapy with Manufacturing Milestone

Onco-Innovations Ltd. is making significant strides in the fight against hard-to-treat cancers by advancing a novel class of DNA Damage Response (DDR) therapies. The company focuses on developing Polynucleotide Kinase Phosphatase (PNKP) inhibitors, which are designed to disrupt cancer cells' ability to repair DNA damage, thereby enhancing the effectiveness of conventional treatments like radiation and chemotherapy. A key milestone was recently achieved with the successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010. This manufacturing breakthrough is crucial for scaling up production and moving toward clinical trials. Additionally, Onco-Innovations has signed a Letter of Intent with Nanosoft Polymers to support polymer development, drug delivery optimization, and formulation work for ONC010, further strengthening its development pipeline.

Cancer cells often have defective DNA repair mechanisms, which can lead to mutations that promote growth and immune evasion. While conventional DNA-damaging therapies can overwhelm these limited repair capacities, some cancers retain enough repair ability to resist treatment at tolerable doses. Onco-Innovations' PNKP inhibitors aim to block this repair process, making cancer cells more vulnerable to existing therapies. The company's progress in manufacturing and partnerships highlights its commitment to bringing this innovative approach to patients. For more details, read the full article on BioMedWire.

This development is part of a broader effort in oncology to target DNA repair pathways, and Onco-Innovations is positioning itself as a key player in this space. The company's newsroom at ibn.fm/ONNVF provides updates on its progress. As the company moves forward, its success could offer new hope for patients with cancers that are resistant to current treatments.